長期投資家のためのIR情報
バリュートレンド

【6190】フェニックスバイオ
PXBマウスを使った薬効試験受託。
類似企業:
【売上同水準】 リニカル WDBココ

売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
決算期 日付 予・実 売上高
(百万円)
対前回 修正率 修正率 営業利益
(百万円)
対前回 修正率 修正率 経常利益
(百万円)
対前回 修正率 修正率 当期利益
(百万円)
対前回 修正率 修正率
2025.03 2024/11/14 Q2予 1,521 -28.3% -28.3% -253 -218.2% -218.2% -277 -229.4% -229.4% -281 -239.8% -239.8%
2025.03 2024/08/13 Q1予 2,121 0.0% 0.0% 214 0.0% 0.0% 214 0.0% 0.0% 201 0.0% 0.0%
2025.03 2024/05/15 当初予 2,121 - - - 214 - - - 214 - - - 201 - - -
2024.03 2024/05/15 1,715 -5.6% -15.8% 11 +37.5% -95.6% 43 -4.4% -82.8% 26 +8.3% -88.9%
2024.03 2024/02/14 Q3予 1,817 0.0% -10.8% 8 0.0% -96.8% 45 0.0% -82.0% 24 0.0% -89.8%
2024.03 2023/11/14 Q2予 1,817 -10.8% -10.8% 8 -96.8% -96.8% 45 -82.0% -82.0% 24 -89.8% -89.8%
2024.03 2023/08/14 Q1予 2,038 0.0% 0.0% 248 0.0% 0.0% 250 0.0% 0.0% 235 0.0% 0.0%
2024.03 2023/05/15 当初予 2,038 - - - 248 - - - 250 - - - 235 - - -
2023.03 2023/05/15 2,124 +5.1% +21.3% 508 +53.0% +146.6% 511 +57.2% +142.2% 493 +75.4% +149.0%
2023.03 2023/02/14 Q3予 2,021 +15.4% +15.4% 332 +61.2% +61.2% 325 +54.0% +54.0% 281 +41.9% +41.9%
2023.03 2022/11/14 Q2予 1,751 0.0% 0.0% 206 0.0% 0.0% 211 0.0% 0.0% 198 0.0% 0.0%
2023.03 2022/08/12 Q1予 1,751 0.0% 0.0% 206 0.0% 0.0% 211 0.0% 0.0% 198 0.0% 0.0%
2023.03 2022/05/13 当初予 1,751 - - - 206 - - - 211 - - - 198 - - -
2022.03 2022/05/13 1,324 +1.8% -17.1% -167 -7.7% -281.5% -127 +18.6% -239.6% -387 -146.5% -572.0%
2022.03 2022/02/14 Q3予 1,300 0.0% -18.6% -155 0.0% -268.5% -156 0.0% -271.4% -157 0.0% -291.5%
2022.03 2021/11/12 Q2予 1,300 -18.6% -18.6% -155 -268.5% -268.5% -156 -271.4% -271.4% -157 -291.5% -291.5%
2022.03 2021/08/13 Q1予 1,598 0.0% 0.0% 92 0.0% 0.0% 91 0.0% 0.0% 82 0.0% 0.0%
2022.03 2021/05/14 当初予 1,598 - - - 92 - - - 91 - - - 82 - - -
2021.03 2021/05/14 1,013 +2.1% -24.7% -276 +8.0% -452.0% -223 +18.3% -502.7% -238 +16.2% -510.3%
2021.03 2021/02/12 Q3予 992 -26.3% -26.3% -300 -500.0% -500.0% -273 -637.8% -637.8% -284 -628.2% -628.2%
2021.03 2020/11/13 Q2予 1,346 0.0% 0.0% -50 0.0% 0.0% -37 0.0% 0.0% -39 0.0% 0.0%
2021.03 2020/08/12 Q1予 1,346 - - - -50 - - - -37 - - - -39 - - -
2020.03 2020/05/15 修正予 1,310 -4.2% -22.3% -146 -67.8% -224.8% -125 -119.3% -191.2% -415 -603.4% -440.2%
2020.03 2020/02/14 Q3予 1,367 0.0% -19.0% -87 0.0% -174.4% -57 0.0% -141.6% -59 0.0% -148.4%
2020.03 2019/11/14 Q2予 1,367 -19.0% -19.0% -87 -174.4% -174.4% -57 -141.6% -141.6% -59 -148.4% -148.4%
2020.03 2019/08/09 Q1予 1,687 0.0% 0.0% 117 0.0% 0.0% 137 0.0% 0.0% 122 0.0% 0.0%
2020.03 2019/05/15 当初予 1,687 - - - 117 - - - 137 - - - 122 - - -
2019.03 2019/05/15 1,228 -3.8% -18.0% -311 -150.8% -350.8% -279 -146.9% -328.7% -297 -130.2% -385.6%
2019.03 2019/02/14 Q3予 1,277 0.0% -14.8% -124 0.0% -200.0% -113 0.0% -192.6% -129 0.0% -224.0%
2019.03 2018/11/14 Q2予 1,277 -14.8% -14.8% -124 -200.0% -200.0% -113 -192.6% -192.6% -129 -224.0% -224.0%
2019.03 2018/08/10 Q1予 1,498 0.0% 0.0% 124 0.0% 0.0% 122 0.0% 0.0% 104 0.0% 0.0%
2019.03 2018/05/15 当初予 1,498 - - - 124 - - - 122 - - - 104 - - -
2018.03 2018/05/15 902 -1.3% -39.1% -268 -7.2% -201.9% -267 -6.8% -201.9% -270 -6.3% -216.4%
2018.03 2018/03/15 修正予 914 -26.3% -38.2% -250 -580.8% -195.1% -250 -538.6% -195.4% -254 -629.2% -209.5%
2018.03 2018/02/14 Q3予 1,240 0.0% -16.2% 52 0.0% -80.2% 57 0.0% -78.2% 48 0.0% -79.3%
2018.03 2017/11/14 Q2予 1,240 0.0% -16.2% 52 0.0% -80.2% 57 0.0% -78.2% 48 0.0% -79.3%
2018.03 2017/10/17 修正予 1,240 -16.2% -16.2% 52 -80.2% -80.2% 57 -78.2% -78.2% 48 -79.3% -79.3%
2018.03 2017/08/10 Q1予 1,480 0.0% 0.0% 263 0.0% 0.0% 262 0.0% 0.0% 232 0.0% 0.0%
2018.03 2017/05/15 当初予 1,480 - - - 263 - - - 262 - - - 232 - - -
2017.03 2017/05/15 1,228 -3.5% -13.6% 142 -30.0% -59.9% 133 -26.1% -61.7% 128 -17.4% -57.2%
2017.03 2017/02/14 Q3予 1,273 0.0% -10.5% 203 0.0% -42.7% 180 0.0% -48.1% 155 0.0% -48.2%
2017.03 2016/11/14 Q2予 1,273 -10.5% -10.5% 203 -42.7% -42.7% 180 -48.1% -48.1% 155 -48.2% -48.2%
2017.03 2016/08/12 Q1予 1,422 0.0% 0.0% 354 0.0% 0.0% 347 0.0% 0.0% 299 0.0% 0.0%
2017.03 2016/05/13 当初予 1,422 - - - 354 - - - 347 - - - 299 - - -
2016.03 2016/05/13 1,217 - - - 190 - - - 149 - - - 125 - - -
ページトップへ戻る